Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

MET is altered by skipping exon 14 or gene amplification in 1 to 2% of patients with non–small-cell lung cancer. Capmatinib, a MET -specific tyrosine kinase inhibitor, led to a response in 40% of previously treated patients and in 67% of previously untreated patients whose tumors had MET alterations...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-09, Vol.383 (10), p.944-957
Hauptverfasser:	Wolf, Jürgen, Seto, Takashi, Han, Ji-Youn, Reguart, Noemi, Garon, Edward B, Groen, Harry J.M, Tan, Daniel S.W, Hida, Toyoaki, de Jonge, Maja, Orlov, Sergey V, Smit, Egbert F, Souquet, Pierre-Jean, Vansteenkiste, Johan, Hochmair, Maximilian, Felip, Enriqueta, Nishio, Makoto, Thomas, Michael, Ohashi, Kadoaki, Toyozawa, Ryo, Overbeck, Tobias R, de Marinis, Filippo, Kim, Tae-Min, Laack, Eckart, Robeva, Anna, Le Mouhaer, Sylvie, Waldron-Lynch, Maeve, Sankaran, Banu, Balbin, O. Alejandro, Cui, Xiaoming, Giovannini, Monica, Akimov, Mikhail, Heist, Rebecca S
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitumor activity Biomarkers Confidence intervals Copy number Edema Enrollments Gene amplification Hypotheses Kinases Lung cancer Medical prognosis Metastasis Mutation Nausea Non-small cell lung carcinoma Pharmacokinetics Small cell lung carcinoma Statistical analysis Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	MET is altered by skipping exon 14 or gene amplification in 1 to 2% of patients with non–small-cell lung cancer. Capmatinib, a MET -specific tyrosine kinase inhibitor, led to a response in 40% of previously treated patients and in 67% of previously untreated patients whose tumors had MET alterations, with a median response duration of 9 months and 12 months, respectively.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2002787